

OhioHealth Improves Diabetic Retinopathy Testing with LumineticsCore® Autonomous AI



About OhioHealth

- 16 hospitals,
- 100+ primary care sites
- 50-county footprint

The Challenge

OhioHealth identified a significant care gap in diabetic retinopathy testing rates. OhioHealth sought a solution that would:

- Improve diabetes-related eye exam rates
- Deliver real-time results during the patient interaction
- Fit seamlessly into busy primary care workflows

Partnership with Digital Diagnostics

Beginning in 2022, OhioHealth partnered with Digital Diagnostics to implement LumineticsCore®, the first FDA-cleared autonomous AI system for diabetic retinopathy detection. This innovative solution delivers immediate diagnostic results in primary care, with no need for specialist interpretation or manual review.

- Diagnostic, point-of-care diabetes-related eye exams in minutes
- Seamless integration into Epic EMR
- Built-in referral pathways for positive cases

Results

Year 1 vs Year 2 of using LumineticsCore®

162% increase
in eye tests completed in
the primary care setting

1.7x
increase in positive
diagnoses of more-than-
mild diabetic retinopathy



About LumineticsCore®

LumineticsCore® is the first FDA-cleared autonomous AI diagnostic system designed to detect diabetic retinopathy at the point-of-care. With high sensitivity, specificity, and diagnostic accuracy, it helps empower clinicians to close care gaps, improve outcomes, and reduce blindness in people with diabetes—all without overburdening care teams.